Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
Authors:
- Valeriya KuznetsovaVKValeriya Kuznetsova
- Rishi K. KothuruRKRishi K. Kothuru
- Prasad S. AdusumilliPAPrasad S. Adusumilli
- Alfredo Amador-MolinaAAAlfredo Amador-Molina
Open Access
- 25 September 2026
- journal article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- IL7-Receptor–Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic LeukemiaNature Communications, 2026
- Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2026
- T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escapeSignal Transduction and Targeted Therapy, 2022
- CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicityJournal of Hematology & Oncology, 2021
- Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphomaBlood, 2021
- Tumor Antigen Escape from CAR T-cell TherapyCancer Discovery, 2018
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignanciesLeukemia, 2018
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MiceCancer Research, 2015
- Differential Regulation of Human IL-7 Receptor α Expression by IL-7 and TCR SignalingThe Journal of Immunology, 2008